Replimune Group Inc expected to post a loss of 71 cents a share - Earnings Preview
Replimune Group Inc expected to post a loss of 71 cents a share - Earnings Preview
Replimune Group Inc REPL.OQ REPL.O is expected to show no change in quarterly revenue when it reports results on June 22 (estimated) for the period ending March 31 2026
LSEG's mean analyst estimate for Replimune Group Inc is for a loss of 71 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 5 "hold" and 2 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Replimune Group Inc is $4.00, about 60.7% below its last closing price of $10.19
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2025 | -0.88 | -0.89 | -0.77 | Beat | 13.5 |
Sep. 30 2025 | -0.79 | -0.79 | -0.90 | Missed | -14.6 |
Jun. 30 2025 | -0.81 | -0.81 | -0.95 | Missed | -17.7 |
Mar. 31 2025 | -0.75 | -0.75 | -0.82 | Missed | -8.9 |
Dec. 31 2024 | -0.68 | -0.67 | -0.79 | Missed | -17.2 |
Sep. 30 2024 | -0.76 | -0.77 | -0.68 | Beat | 11.2 |
Jun. 30 2024 | -0.84 | -0.85 | -0.78 | Beat | 8.4 |
Mar. 31 2024 | -0.79 | -0.79 | -0.82 | Missed | -3.5 |
This summary was machine generated June 19 at 11:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Replimune
See all newsTrump picks White House adviser Heidi Overton to run FDA, source says (updated)
Brief: Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed
Brief: Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update
Replimune Q1 net loss narrows as expenses decline
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly